Crossmark

Successful treatment of three patients with human immunodeficiency virus and hepatitis C virus genotype 1b co-infection by daclatasvir plus asunaprevir

Crossref DOI link: https://doi.org/10.1007/s12328-016-0693-0

Published Online: 2016-10-20

Published Print: 2017-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Hirashima, Noboru

Iwase, Hiroaki

Shimada, Masaaki

Ryuge, Nobumitsu

Imamura, Junji

Ikeda, Hiroki

Tanaka, Yasuhito

Matsumoto, Nobuyuki

Okuse, Chiaki

Itoh, Fumio

Yokomaku, Yoshiyuki

Watanabe, Tsunamasa
Funding

Funding for this research was provided by:

Japan Agency for Medical Research and Development
License Information

Text and Data Mining valid from 2016-10-20

Version of Record valid from 2016-10-20
More Information

Article History

Received: 13 August 2016

Accepted: 7 October 2016

First Online: 20 October 2016

Compliance with ethical standards

:

: Noboru Hirashima, Hiroaki Iwase, Masaaki Shimada, Nobumitsu Ryuge, Junji Imamura, Hiroki Ikeda, Yasuhito Tanaka, Nobuyuki Matsumoto, Chiaki Okuse, Fumio Itoh, Yoshiyuki Yokomaku and Tsunamasa Watanabe declare that they have no conflict of interest.

: All procedures followed have been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.

: Informed consent was obtained from all patients for inclusion in the study.

Document is current

Any future updates will be listed below